An estimated 80% of cardiovascular disease (CVD), including heart disease and stroke, is preventable. However, CVD remains the leading cause of death and the most expensive disease, costing nearly $1 billion a day.1
Guidelines are evolving to implement new kinds of cardiovascular diagnostic and prognostic testing services aimed at prevention and early intervention.
Quest Diagnostics is at the forefront, committed to providing innovative solutions that provide additional and complementary insight to help identify those most at risk.
Going beyond standard lipid panels to assess lipoprotein, apolipoprotein, inflammatory, metabolic, and genetic risk factors may provide deeper insights into the residual risk of your patients.
Advanced biomarkers have been shown to help identify residual risk and have been adopted by several practice guidelines and professional societies.2,3 With deeper insights, you can take further action to help reduce your patients’ risk for adverse cardiovascular events.
Nearly 50% of all heart attacks and strokes occur in patients with “normal” cholesterol levels. Recent evidence goes beyond lipids to suggest that inflammation within the artery wall is the primary contributor to this residual risk for heart attack and stroke. Inflammation contributes to both vulnerable plaque formation and to plaque rupture.4
The beginnings of CVD are rooted in injury to the arterial wall. Risk factors like smoking, hypertension, and diabetes injure the arterial wall, making it more susceptible to penetration and accumulation of excess lipids.
The inflammatory response to injury contributes to the progression of plaque development and is a key factor in the formation of vulnerable plaque and plaque rupture, which may cause a heart attack or stroke.
Patients who have metabolic syndrome are at higher risk of multiple chronic conditions, including diabetes, coronary heart disease, and cancer, as well as stroke. Metabolic syndrome has become increasingly common: its prevalence has risen in every sociodemographic group, and today it is estimated that more than a third of adults in the United States have metabolic risk.5
The recently updated ACCF/AHA guidelines for the management of heart failure recommend BNP or NT-proBNP biomarker testing followed by early intervention as an aid for prevention. Quest offers advanced biomarker testing to help prevent heart failure in your at-risk patients.
In many patients, the risk of CVD may be attributed to nonlipid factors, including genetic polymorphisms and mutations. Quest offers cardiogenetic testing to aid in early diagnosis and earlier treatment for affected patients as well as family members.
Cardiovascular disease (CVD) is the leading cause of death in women, taking the lives of over 300,000 women in the US in 2020.6
While women and men share the 3 most common risk factors for CVD—hypertension, high low-density lipoproteincholesterol (LDL-C), and smoking6-8—there are unique risk-enhancing factors for women at every stage of life.
With more people at risk for cardiovascular disease than ever before, the Quest Cardiometabolic Center of Excellence™ at Cleveland HeartLab® is advancing a prevention-focused approach for heart disease and associated metabolic conditions.
CVD is strongly associated with T2DM, CKD, and NAFLD. Through significant investments in novel technology, the Cleveland HeartLab® is fostering innovation to detect these conditions in their early stages, providing the opportunity for stage-targeted intervention and improved clinical outcomes.
This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.
References
Your Quest account representative can provide additional information on our cardiovascular testing solutions.
Cardiovascular disease
Avoid disruptions and reduce paperwork with electronic billing trailers.
Access better patient tools, view test offerings, improve your bottom line, and more.
Your Privacy Choices
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services.
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.
